CDK4 and neoplasm: Thus, the association between changes in serum TK1 activity and tumor Ki-67 response to palbociclib observed in the NeoPalAna trial provides the foundation for future exploration of the potential predictive nature of serum TK1 activity on response and progression-free survival in patients receiving CDK4/6 inhibitors for  metastatic disease.